



EIKO LIFESCIENCES LIMITED

F E E L T H E C H E M I S T R Y

Ref. No.: EIKO/BSE/2024-25/12

Date: 30th May,2024

To,
Corporate Services Department
BSE Limited
Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai – 400001

BSE Scrip Code:- 540204

Dear Sir/ Madam,

We wish to inform that the company has incorporated a Limited Liability Partnership namely “**Eiko Scientific Solutions LLP**” on May 30, 2024, under **LLPIN: ACH 4311**. Disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and other applicable circulars, if any, is enclosed herewith as “**Annexure A**”.

Kindly take the above on record and oblige.

For Eiko Lifesciences Limited

Chintan Doshi
Company Secretary and Compliance Officer
Membership No: ACS 36190

Encl. As Above



Annexure A

Name of the target entity, details in brief such as size, turnover etc.	Name: EIKO SCIENTIFIC SOLUTIONS LLP LLPIN: ACH-4311 Contribution: 5,00,000 (Rupees Five Lakhs Only) Turn over: Nil (Yet to commence business operations)
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Eiko Scientific Solutions LLP is formed with Eiko Lifesciences Limited (holding 99.99%) as its Designated Partner Accordingly, Eiko Scientific Solutions LLP is a related party
Industry to which the entity being acquired belongs	Chemical
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The venture focuses on clinical research, development, and innovation in specialty chemicals, healthcare, and other medical fields, including the import and export of innovative technologies. The Board has approved an investment of up to INR 5 crore over the next three years to support this initiative.
Brief details of any government or Regulatory approval required for the acquisition.	NA
Indicative time period for completion of the acquisition	NA
Nature of consideration – whether each consideration or share swap and details of the same	Cash Consideration
Contribution	Rs. 4,99,999/-
Control acquired	99.99%
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, country in which the acquired entity has presence and any other significant information (in brief)	Brief background: Eiko Scientific Solutions LLP is incorporated under the Limited Liability Partnership Act 2008 and registered with Registrar of Companies Mumbai on 30 th May, 2024, and is yet to commence its business operations.